<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230316057741N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-09</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ketamine along with gabapentin on complications of spinal anesthesia in caesarean section</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of ketamine with gabapentin on the severity of some complications of spinal anesthesia in cesarean section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69305</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, eligible patients are randomly divided into four groups. Randomization will be simple and individual. The names of each patient will be written as a number on a piece of paper and will be placed inside the appropriate envelopes, four people will randomly remove them from the envelopes and each will enter one of the four groups, Blinding description: Care provider  will not informed about the type of intervention received by patients.</study_design>
      <phase>3</phase>
      <hc_freetext>Complications after cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention first group: Receive gabapentin (single oral dose, 300 mg) 30 minutes before surgery. Intervention 2: Intervention second group:  Ketamine (intravenous dose of 0.25mg/kg as a single bolus dose) five minutes after cord clamping. Intervention 3: Intervention third group: ُSimultaneous administration of ketamine (intravenous dose of 0.25 mg/kg as a single bolus dose) along with gabapentin (single oral dose, 300 mg). Intervention 4: Control group:  Receiving placebo (intravenous distilled water).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The intended data that is the result of this study and can be published includes the results of the study and the data of participants without names and identity information after the study is conducted and if necessary after the publication of the article from this study with the person responsible and responsible for the project. It can be shared if you contact them.

When:
The access period starts 3 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
The data obtained from this study is only allowed for further study and further analysis is also allowed for review studies and meta-analysis and otherwise it will not be available for other matters.

Where to obtain:
zasadik66@gmail.com

How to obtain:
Eligible people to receive documents must send a written and signed letter from the scientific institute or the scientific board of one of the universities to the given email address.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Asadi Kalemeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>International Affairs Office, Central Library, Yasuj University of Medical Sciences, Shahid Dr. Jalil St., Yasuj, Kohgilouyeh and Boyer-Ahmad Province, Iran.</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591741417</zip>
        <telephone>+98 74 3323 3257</telephone>
        <email>zasadik66@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Asadi Kalemeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>International Affairs Office, Central Library, Yasuj University of Medical Sciences, Shahid Dr. Jalil St., Yasuj, Kohgilouyeh and Boyer-Ahmad Province, Iran.</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591741417</zip>
        <telephone>+98 74 3323 3257</telephone>
        <email>zasadik66@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No emergency C/S surgery
No emergency C/S surgery
No emergency C/S surgery
Type of surgical incision on the skin of Von Stilweber on the uterus, transverse incision on the lower uterine segment (kerr)
Absence of underlying disease such as weak immune system, diabetes, high blood pressure, cardiopulmonary disease, blood disease, autoimmune disease, severe liver hepatitis, asthma, pancreatitis, or coagulation disorders.
Singleton pregnancy
Not taking special medicine
Gestational age greater than or equal to 28 weeks
Being in the low risk group based on the risk factors of PPH, including placenta previa, placental abruption, hypertension, HELLP syndrome, macrosomia, non-cephalic presentation, intrauterine infection or the use of assisted reproductive technology (ART).
Mother's BMI based on pre-pregnancy weight less than 30 kg/m2
Natural plt counting</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>34 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Any contraindications for spinal anesthesia
Any contraindications to receiving ketamine or gabapentin
Severe bleeding during C/S
If any of the patients in the placebo group suffer from any of the side effects that cannot be tolerated by the patient, the patient will be treated for the side effects with the opinion of the relevant specialist, and the patient will be excluded from the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z38.01</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Single liveborn infant, delivered by cesarean</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention first group: Receive gabapentin (single oral dose, 300 mg) 30 minutes before surgery.</i_keyword>
      <i_keyword>Intervention second group:  Ketamine (intravenous dose of 0.25mg/kg as a single bolus dose) five minutes after cord clamping.</i_keyword>
      <i_keyword>Intervention third group: ُSimultaneous administration of ketamine (intravenous dose of 0.25 mg/kg as a single bolus dose) along with gabapentin (single oral dose, 300 mg)</i_keyword>
      <i_keyword>Control group:  Receiving placebo (intravenous distilled water)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of postoperative nausea and vomiting. Timepoint: Their nausea and vomiting at intervals of 1, 2, 3, 4 and 6 hours. Method of measurement: A Visual Analogue Scale will be used to measure the severity of nausea and vomiting after the operation.</prim_outcome>
      <prim_outcome>Severity of postoperative headache. Timepoint: Headache at intervals of 1, 6, 12 hours after the operation. Method of measurement: A Visual Analogue Scale will be used to measure the severity of headache.</prim_outcome>
      <prim_outcome>Postoperative patient satisfaction score. Timepoint: Post-operation. Method of measurement: A Visual Analogue Scale will be used to measure the patient satisfaction.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-15</approval_date>
        <contact_name>Ethics Committee of Yasouj University of Medical Sciences</contact_name>
        <contact_address>Yasouj University of Medical Sciences, MHHQ+493, Shahid Motahari Blvd, Kohgiluyeh and Boyer-Ahmad Province, Yasuj Yasuj Kohgilouyeh-va-Boyrahmad Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
